Pulmonx Corp reported results for the 2026 quarter with revenue of $22.76M and a net loss of ($10.08M), or diluted EPS of ($0.24), representing improvement versus the prior-year quarter.Financial Highlights¹ Reported as “Revenue”. ² Reported as “Net loss”. ³ Reported as “loss per share attributable…
Q2 2026 revenue reached $22.8M, with net loss and adjusted EBITDA loss both significantly reduced year-over-year. Gross margin improved to 78%, and cost alignment initiatives drove a 16% decrease in operating expenses. Full-year guidance is reaffirmed, with China shipments set to resume in early 20…
Q2 2026 revenue reached $22.8M, with net loss and adjusted EBITDA loss both significantly reduced year-over-year. Gross margin improved to 78%, and the company reiterated full-year revenue guidance of $90–$92M, expecting growth to accelerate as China resumes and U.S. sales force ramps.Based on Pulm…
REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation NASDAQ:LUNG (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, July…
